// App-Quantinova.ai

LB-104 : Quantification of the preclinical and clinical relationship between pRAD50 and efficacy after treatment with the ATR inhibitor ceralasertib (AZD6738)

Researchers

Presenter

  • James William Thomas Yates

Principal Investigators

  • Zena Wilson

  • Gemma N. Jones

  • Kevin Harrington

  • Matthew Krebs

  • Magnus Dillon

  • Andrew J. Pierce

  • Emma Dean

  • Alan Lau

Medical Centers

  • AstraZeneca R&D, Saffron Walden, United Kingdom.

  • The Royal Marsden Hospital, London, United Kingdom

  • The Christie NHS Foundation TRUST, Manchester, United Kingdom

  • Institute for Cancer Research, London, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Ataxia telangiectasia

  • Solid malignancies

  • Seizures sensorineural deafness ataxia mental retardation electrolyte imbalance

  • Diffuse large B-cell lymphoma

  • Non Small Cell Lung cancer

  • Squamous cell carcinoma of the head and neck

  • Triple-negative breast cancer

Biomarkers

  • Ataxia Telangiectasia And Rad3-Related Protein

  • Ataxia-telangiectasia mutated

Drug/Treatment

  • Durvalumab

  • Olaparib

  • AZD6738

Outcome

  • N/A

Study Design

  • Randomized

  • Pharmacokinetics

  • Pharmacodynamics

Phase

  • I

Study Id's

  • NCT02223923

  • NCT02264678

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved